Pharmaceutical manufacturers are directing unprecedented capital toward sterile fill-finish infrastructure to clear persistent GLP-1 receptor agonist shortages.
Contract Manufacturing Demand
Third-party contract development and manufacturing organizations (CDMOs) report full capacity utilization, pushing drugmakers to acquire proprietary production sites directly.